JP2021523696A5 - - Google Patents
Info
- Publication number
- JP2021523696A5 JP2021523696A5 JP2020558973A JP2020558973A JP2021523696A5 JP 2021523696 A5 JP2021523696 A5 JP 2021523696A5 JP 2020558973 A JP2020558973 A JP 2020558973A JP 2020558973 A JP2020558973 A JP 2020558973A JP 2021523696 A5 JP2021523696 A5 JP 2021523696A5
- Authority
- JP
- Japan
- Prior art keywords
- activity
- snca
- composition according
- vector
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024019364A JP2024073420A (ja) | 2018-04-23 | 2024-02-13 | Dnaメチル化の標的化された編集によるsnca発現の下方調節 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661134P | 2018-04-23 | 2018-04-23 | |
| US62/661,134 | 2018-04-23 | ||
| US201862676149P | 2018-05-24 | 2018-05-24 | |
| US62/676,149 | 2018-05-24 | ||
| US201962789932P | 2019-01-08 | 2019-01-08 | |
| US62/789,932 | 2019-01-08 | ||
| US201962824195P | 2019-03-26 | 2019-03-26 | |
| US62/824,195 | 2019-03-26 | ||
| PCT/US2019/028786 WO2019209869A2 (en) | 2018-04-23 | 2019-04-23 | Downregulation of snca expression by targeted editing of dna-methylation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019364A Division JP2024073420A (ja) | 2018-04-23 | 2024-02-13 | Dnaメチル化の標的化された編集によるsnca発現の下方調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523696A JP2021523696A (ja) | 2021-09-09 |
| JP2021523696A5 true JP2021523696A5 (cg-RX-API-DMAC7.html) | 2022-05-06 |
Family
ID=68294262
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558973A Pending JP2021523696A (ja) | 2018-04-23 | 2019-04-23 | Dnaメチル化の標的化された編集によるsnca発現の下方調節 |
| JP2024019364A Pending JP2024073420A (ja) | 2018-04-23 | 2024-02-13 | Dnaメチル化の標的化された編集によるsnca発現の下方調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019364A Pending JP2024073420A (ja) | 2018-04-23 | 2024-02-13 | Dnaメチル化の標的化された編集によるsnca発現の下方調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210189361A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3784785A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021523696A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112166194A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019261361A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3097755A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019209869A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019255789B2 (en) | 2018-04-19 | 2025-11-20 | The Regents Of The University Of California | Compositions and methods for gene editing |
| SG11202102012SA (en) * | 2018-08-28 | 2021-04-29 | Pharos Vaccine Inc | Improved lentiviral vector |
| BR112021021178A2 (pt) | 2019-04-26 | 2022-03-15 | Allogene Therapeutics Inc | Receptores de antígeno quimérico resistentes ao rituximabe e usos destes |
| US20220325346A1 (en) * | 2019-07-09 | 2022-10-13 | Selonterra, Inc. | Use of snca-mediated genes for diagnosis and treatment of parkinson's disease |
| GB202010075D0 (en) * | 2020-07-01 | 2020-08-12 | Imp College Innovations Ltd | Therapeutic nucleic acids, peptides and uses |
| CN117897167A (zh) * | 2021-05-13 | 2024-04-16 | 福奇生物制品公司 | 腺病毒辅助质粒 |
| CN114790463B (zh) * | 2022-04-15 | 2023-10-13 | 中山大学 | 稳定转染CRISPR/dCas9系统的单克隆细胞株的构建方法及其应用 |
| EP4342988A1 (en) | 2022-09-20 | 2024-03-27 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Compositions and methods for modification of the expression of a snca gene |
| CN120230839A (zh) * | 2025-04-30 | 2025-07-01 | 北京凯祥弘康生物科技有限公司 | 一种检测snca基因dna甲基化水平的引物探针组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014197748A2 (en) * | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| KR20250012194A (ko) * | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| WO2015089419A2 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| US10676726B2 (en) * | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| US20170035860A1 (en) * | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
| EP3091087A1 (en) * | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| AU2016279062A1 (en) * | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
| MX2019002004A (es) * | 2016-08-19 | 2019-10-09 | Whitehead Inst Biomedical Res | Metodos para editar la metilacion del adn. |
| WO2018154418A1 (en) * | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
-
2019
- 2019-04-23 JP JP2020558973A patent/JP2021523696A/ja active Pending
- 2019-04-23 EP EP19793162.9A patent/EP3784785A4/en not_active Withdrawn
- 2019-04-23 US US17/050,009 patent/US20210189361A1/en not_active Abandoned
- 2019-04-23 CN CN201980035381.8A patent/CN112166194A/zh active Pending
- 2019-04-23 AU AU2019261361A patent/AU2019261361A1/en not_active Abandoned
- 2019-04-23 WO PCT/US2019/028786 patent/WO2019209869A2/en not_active Ceased
- 2019-04-23 CA CA3097755A patent/CA3097755A1/en active Pending
-
2024
- 2024-02-13 JP JP2024019364A patent/JP2024073420A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trappe et al. | Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study | |
| Hu et al. | Hydroxychloroquine attenuates neuroinflammation following traumatic brain injury by regulating the TLR4/NF-κB signaling pathway | |
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| Potter et al. | 1, 25‐dihydroxyvitamin D3 and its nuclear receptor repress human α1 (I) collagen expression and type I collagen formation | |
| Novak et al. | Macrophage activation and skeletal muscle healing following traumatic injury | |
| Ge et al. | USP1/UAF1-stabilized METTL3 promotes reactive astrogliosis and improves functional recovery after spinal cord injury through m6A modification of YAP1 mRNA | |
| Sides et al. | The Epstein-Barr virus latent membrane protein 1 and transforming growth factor–β1 synergistically induce epithelial–mesenchymal transition in lung epithelial cells | |
| JP2019517815A5 (cg-RX-API-DMAC7.html) | ||
| Heo et al. | Transcriptional profiles of mouse oligodendrocyte precursor cells across the lifespan | |
| Yu et al. | 1, 25 (OH) 2D3 attenuates pulmonary arterial hypertension via microRNA-204 mediated Tgfbr2/Smad signaling | |
| Zhang et al. | Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment | |
| Moreno-Igoa et al. | Fragment C of tetanus toxin, more than a carrier. Novel perspectives in non-viral ALS gene therapy | |
| Ramadass et al. | Type I collagen and its daughter peptides for targeting mucosal healing in ulcerative colitis: A new treatment strategy | |
| Zhao et al. | A mesenchymal stem cell aging framework, from mechanisms to strategies | |
| JP2022512974A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Role of sphingosine‐1‐phosphate receptors in vascular injury of inflammatory bowel disease | |
| ES2936383T3 (es) | Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio | |
| CN107137710B (zh) | Kindlin-2蛋白作为靶点在制备治疗肾炎的药物中的应用 | |
| Heo et al. | Transcriptional profiles of murine oligodendrocyte precursor cells across the lifespan | |
| Bloom et al. | Replication-competent controlled herpes simplex virus | |
| Lavrnja et al. | The effect of ribavirin on reactive astrogliosis in experimental autoimmune encephalomyelitis | |
| WO2024084243A1 (en) | Novel reprogramming method | |
| US5798334A (en) | Pharmaceutical compositions for scarless tissue repair and regeneration and methods related thereto | |
| Zhu et al. | Senomorphic, senolytic, and rejuvenation therapies | |
| Sengun et al. | Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits |